- Conditions
- Non-small Cell Lung Cancer
- Interventions
- REGN2810, REGN2810/chemo/ipi, Chemotherapy, Placebo
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 789 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 9
- States / cities
- Rancho Mirage, California • Riverside, California • Whittier, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 640
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 1,673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 928
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 580 more
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Abiraterone Acetate, Apalutamide, Cabazitaxel, Carboplatin, Ipilimumab, Laboratory Biomarker Analysis, Prednisone
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 3
- States / cities
- Houston, Texas • Sugar Land, Texas
- Conditions
- Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
- Interventions
- Indoximod, Ipilimumab, Nivolumab, Pembrolizumab
- Drug
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 6
- States / cities
- Augusta, Georgia • Iowa City, Iowa • Rochester, Minnesota + 3 more
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- aldesleukin, ipilimumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Urothelial Cancer
- Interventions
- Nivolumab, Ipilimumab, Gemcitabine, Cisplatin, Carboplatin
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 29
- States / cities
- Anchorage, Alaska • Fresno, California • Santa Rosa, California + 24 more
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- High-risk Muscle Invasive Urothelial Carcinoma
- Interventions
- Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab, Enfortumab vedotin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 19
- States / cities
- Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more
- Conditions
- Multiple Myeloma, Lymphoma
- Interventions
- Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, T-Cell Non-Hodgkin Lymphoma
- Interventions
- Ipilimumab, Lenalidomide
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Unresectable Stage III or IV Malignant Melanoma
- Interventions
- Ipilimumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 3
- States / cities
- Palm Springs, California • Santa Monica, California • Boston, Massachusetts
- Conditions
- Advanced Cancers, Melanoma
- Interventions
- MGN1703, Ipilimumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Unresectable or Metastatic Melanoma
- Interventions
- Nivolumab, Ipilimumab, Placebo for Nivolumab, Placebo for Ipilimumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 945 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 35 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma
- Interventions
- Ipilimumab, Nivolumab, Prednisone, Tacrolimus
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Neuroendocrine Carcinoma, Neuroendocrine Tumors
- Interventions
- Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab
- Biological · Drug
- Lead sponsor
- Peter Hosein, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Uveal Melanoma, Hepatic Metastases
- Interventions
- SIR-Spheres® Yttrium 90, ipilimumab, nivolumab
- Device · Drug
- Lead sponsor
- David Minor, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Philadelphia, Pennsylvania
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Interventions
- Ipilimumab, Placebo, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 24 more
- Conditions
- Breast Cancer, Adenocarcinoma
- Interventions
- MDX-010
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 14
- States / cities
- San Diego, California • Indianapolis, Indiana • Jeffersonville, Indiana + 7 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Niraparib + Nivolumab, Niraparib + Ipilimumab
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Ipilimumab, Paclitaxel, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVC Major Salivary Gland Carcinoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- RP2, Ipilimumab, Nivolumab
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Buffalo, New York • Milwaukee, Wisconsin
- Conditions
- Bladder Cancer
- Interventions
- Nivolumab, Ipilimumab, Radical cystectomy
- Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more